Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the partnership, Altruix has been selected as a limited distribution partner for Brixadi (buprenorphine), an opioid medication and an extended-release subcutaneous injection indicated for the treatment of moderate to severe opioid use disorder patients.
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: Brixadi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Altruix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 17, 2023
Details:
BRIXADI is an investigational, extended-release SC injectable therapy under review by FDA for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product.
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: Brixadi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
BRIXADI, SC injection, will be indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: Brixadi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
BRIXADI is an investigational, extended-release injection for subcutaneous use that is under review by FDA for the treatment of moderate to severe opioid use disorder, and expects to receive a PDUFA date in 30 days.
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: Buvidal
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021